Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study
X Li, H Dai, X Li, M Han, J Li, A Suhner, R Lin… - Graefe's archive for …, 2019 - Springer
X Li, H Dai, X Li, M Han, J Li, A Suhner, R Lin, S Wolf, REFINE study group
Graefe's archive for clinical and experimental ophthalmology, 2019•SpringerPurpose To demonstrate the efficacy and safety of ranibizumab 0.5 mg pro re nata (PRN)
versus laser photocoagulation for the treatment of Chinese patients with visual impairment
due to diabetic macular edema (DME). Methods REFINE was a phase III, 12-month, double-
masked, multicenter, laser-controlled study in patients (aged≥ 18 years) with DME. Patients
were randomized 4: 1 to receive either ranibizumab 0.5 mg or laser dosing regimen. Efficacy
was evaluated as mean average change in best-corrected visual acuity (BCVA) from Months …
versus laser photocoagulation for the treatment of Chinese patients with visual impairment
due to diabetic macular edema (DME). Methods REFINE was a phase III, 12-month, double-
masked, multicenter, laser-controlled study in patients (aged≥ 18 years) with DME. Patients
were randomized 4: 1 to receive either ranibizumab 0.5 mg or laser dosing regimen. Efficacy
was evaluated as mean average change in best-corrected visual acuity (BCVA) from Months …
Purpose
To demonstrate the efficacy and safety of ranibizumab 0.5 mg pro re nata (PRN) versus laser photocoagulation for the treatment of Chinese patients with visual impairment due to diabetic macular edema (DME).
Methods
REFINE was a phase III, 12-month, double-masked, multicenter, laser-controlled study in patients (aged ≥ 18 years) with DME. Patients were randomized 4:1 to receive either ranibizumab 0.5 mg or laser dosing regimen. Efficacy was evaluated as mean average change in best-corrected visual acuity (BCVA) from Months 1 to 12 versus baseline (primary endpoint), anatomical outcomes, treatment exposure, and safety were also assessed.
Results
Ranibizumab was statistically superior (p < 0.001) to laser treatment, with a mean average BCVA gain of 6.8 letters (ranibizumab) over 12 months versus 1.1 letters (laser). At Month 12, mean BCVA gain was 7.8 letters (ranibizumab) and 2.5 letters (laser) from baseline. Patients in the ranibizumab arm received a mean number of 7.9 intravitreal injections, whereas those in the laser arm received a mean of 2.1 treatments. There were no new safety signals.
Conclusion
Ranibizumab 0.5 mg PRN demonstrated a statistically significant and clinically meaningful treatment effect versus laser and was well tolerated in Chinese patients with visual impairment due to DME over 12 months.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果